DOCSLIB.ORG

(12) Patent Application Publication (10) Pub. No.: US 2003/0180352 A1 Patel Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) Patent Application Publication (10) Pub. No.: US 2003/0180352 A1 Patel Et Al US 2003018O352A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2003/0180352 A1 Patel et al. (43) Pub. Date: Sep. 25, 2003 (54) SOLID CARRIERS FOR IMPROVED Publication Classification DELIVERY OF ACTIVE INGREDIENTS IN PHARMACEUTICAL COMPOSITIONS (51) Int. Cl." ........................ A61K 31/4439; A61K 9/20 (52) U.S. Cl. ............................................ 424/465; 514/338 (76) Inventors: Mahesh V. Patel, Salt Lake City, UT (US); Feng-Jing Chen, Salt Lake City, UT (US) (57) ABSTRACT Correspondence Address: The present invention provides Solid pharmaceutical com REED & ASSOCATES positions for improved delivery of a wide variety of active 800 MENLO AVENUE ingredients contained therein or Separately administered. In SUTE 210 one embodiment, the Solid pharmaceutical composition MENLO PARK, CA 94025 (US) includes a Solid carrier, the Solid carrier including a Substrate and an encapsulation coat on the Substrate. The encapsula (21) Appl. No.: 10/159,601 tion coat can include different combinations of active ingre (22) Filed: May 30, 2002 dients, hydrophilic Surfactant, lipophilic Surfactants and triglycerides, and Solubilizers. In another embodiment, the Related U.S. Application Data Solid pharmaceutical composition includes a Solid carrier, the solid carrier being formed of different combinations of (60) Continuation-in-part of application No. 09/800,593, active ingredients, hydrophilic Surfactants, lipophilic Surfac filed on Mar. 6, 2001, which is a division of appli tants and triglycerides, and Solubilizers. The compositions of cation No. 09/447,690, filed on Nov. 23, 1999, now the present invention can be used for improved delivery of Pat. No. 6,248,363. active ingredients. Patent Application Publication Sep. 25, 2003 Sheet 1 of 4 US 2003/0180352 A1 6 O 4 O --Present invention; Example 2 -O-Commercial Product; Micronase -e-Pure Bulk Drug O 60 120 180 Time (min) FIG. 1 Patent Application Publication Sep. 25, 2003 Sheet 2 of 4 US 2003/0180352 A1 1OO s :C 80 CD CDY U - EE 2 60 O D .2 ?h 5CD 40 98 -- Present invention; Example 6 O) 20 f -8-Present Invention; Example 3 -e-Pure Bulk Drug O O 60 120 18O Time (min) FIG. 2A Patent Application Publication Sep. 25, 2003 Sheet 3 of 4 US 2003/0180352 A1 30 -- Present invention; Example 6 -8-Present invention; Example 3 -O- Commercial Product; Prometrium O -e-Pure Bulk Drug 2 10 O 60 120 18O Time (min) FIG. 2B Patent Application Publication Sep. 25, 2003 Sheet 4 of 4 US 2003/0180352 A1 100 8 O 6 O -- Present invention; Example 8 --Present Invention; Example 7 -O- Commercial Product; Prilosec O 15 30 45 60 Time (min) FIG. 3 US 2003/018O352 A1 Sep. 25, 2003 SOLID CARRIERS FOR IMPROVED DELIVERY 0008. In addition, it is well known that active ingredients OF ACTIVE INGREDIENTS IN that are acid-labile, will degrade quickly when placed in PHARMACEUTICAL COMPOSITIONS contact with acids. An enteric coating therefore is typically applied to a core containing Such acid-labile drugs was 0001 CROSS REFERENCE To RELATED APPLICA applied to prevent the drug from contacting the acidic pH TIONS conditions of the Stomach upon oral administration. The 0002 This application is a continuation-in-part of U.S. acidic residue of the enteric coating, however, can degrade Ser. No. 09/800,593 filed on Mar. 6, 2001, which is a the acid-labile drug during Storage. To Solve this problem, a divisional of U.S. Ser. No. 09/447,690, filed on Nov. 23, Significant amount of inorganic alkaline materials were 1999, now issued as U.S. Pat. No. 6,248,363. introduced to the core by Specific processes, Such as granu lation So as to ensure the acid-labile drug being evenly in FIELD OF THE INVENTION contact with the basic inorganic Salt. 0003. The present invention relates to pharmaceutical 0009 Thus, there is a need for pharmaceutical composi delivery Systems for pharmaceutical active ingredients, Such tions and dosage forms, and methods therefor, that do not as drugs, nutritionals, cosmeceuticals, and diagnostic agents. Suffer from the foregoing disadvantages. Further, there In particular, the present invention provides compositions remains a need for Stable formulations of active ingredients and dosage forms including Solid carriers for improved Such as acid-labile compounds, that have minimal limita delivery of pharmaceutical active ingredients. tions with regards to processing techniqueS or material Selection. BACKGROUND OF THE INVENTION 0004 Hydrophobic active ingredients, such as progest SUMMARY OF THE INVENTION erone, cycloSporin, itraconazole and glyburide present deliv 0010. It is an object of the invention to provide solid ery challenges due to their poor aqueous Solubility and slow pharmaceutical compositions having active ingredients in a dissolution rate. Several commercial products of these hydrophobic drugs are available, the various products using rapid dissolvable and more solubilized state therein. different methods to try to enhance in Vivo performance. 0011. It is another object of the invention to provide solid One approach is size reduction by micronization, Such as in pharmaceutical compositions having more rapid dissolution Prometrium (micronized progesterone) and Micronase upon administration to a patient. (micronized glyburide). Other approaches include size reduction in emulsion formulations, Such as in Sandimmune 0012. It is another object of the invention to provide solid (cyclosporin emulsion) and NeOral (cyclosporin micro pharmaceutical compositions having more Sustained and emulsion). These approaches Suffer from Several disadvan complete Solubilization upon administration to a patient. tages. Micronization/nanonization presents processing and 0013. It is another object of the invention to provide solid Stability challenges, as well as dissolution limitations, Since pharmaceutical compositions capable of delivery a wide the micronized/nanosized drug Still possesses a high degree variety of pharmaceutical active ingredients. of crystallinity. Liquid formulations present drug precipita tion and packaging challenges, due to Solvent evaporation. 0014. It is another object of the invention to provide solid Moreover, non-Solid formulations are more prone to chemi pharmaceutical compositions of coated Substrate materials cal instability and capsule-Shell incompatibility, leading to without the need for binders. the possibility of leakage upon Storage. 0015. It is another object of the invention to provide solid 0005 Solid carriers for pharmaceutical active ingredients pharmaceutical compositions having increased chemical Sta offer potential advantages over micronized drugs, emulsions bility of the active ingredient or Solubilized formulations. Solid carriers, typically of size 0016. It is another object of the invention to provide solid less than about 2 mm, can easily pass through the Stomach, pharmaceutical compositions having increased chemical Sta thus making the performance leSS prone to gastric emptying bility of the active ingredient upon prolonged Storage. variability. Further, the problems of leakage and other dis advantages of liquid formulations are not present in Solid 0017. It is another object of the invention to provide solid carrier formulations. To date, however, Such Solid carrier pharmaceutical compositions having increased chemical Sta formulations generally have been limited to a few specific bility of the active ingredient in the gastrointestinal tract drugs, due to difficulties in formulating appropriate drug/ upon administration. excipient compositions to effectively coat the active ingre 0018. It is another object of the invention to provide solid dient onto a carrier particle. pharmaceutical compositions remaining Stable upon expo 0006 Conventional Solid dosage forms of hydrophobic Sure to moisture and/or acidic species, Such as protons. active ingredients, Such as tablets, or multiparticulates in capsules, often exhibit slow and incomplete dissolution and 0019. It is another object of the invention to provide solid Subsequent absorption. These formulations often show a pharmaceutical compositions having increased chemical Sta high propensity for biovariability and food interactions of bility of the active ingredient, without the need for the active the active ingredient, resulting in restrictive compliance/ ingredient to be evenly in contact with a basic inorganic Salt. labeling requirements. 0020. It is another object of the invention to provide solid 0007 Due to the slow dissolution and dependence on pharmaceutical compositions having Stable active ingredi gastric emptying, Solid dosage forms often delay the onset of ents, without the need for the inclusion of a basic inorganic Some hydrophobic active ingredients. Salt in the composition. US 2003/018O352 A1 Sep. 25, 2003 0021. It is another object of the invention to provide solid 0033. In another embodiment, the solid pharmaceutical pharmaceutical compositions having Stable active ingredi composition includes a Solid carrier, the Solid carrier includ ents, without the need for an enteric coating. ing a Substrate and an encapsulation coat on the Substrate. The encapsulation coat includes an active ingredient and an 0022. It is another object of the invention to provide solid ionic or non-ionic hydrophilic Surfactant, an active ingredi pharmaceutical compositions having minimal limitations ent and a lipophilic component Such as a lipophilic Surfac with regard to processing techniqueS or material Selection. tant or a triglyceride, or an active ingredient and both a 0023. It is another object
Load more

Recommended publications
  • CHAPTER 29 ORGANIC CHEMICALS VI 29-1 Notes 1
    )&f1y3X CHAPTER 29 ORGANIC CHEMICALS VI 29-1 Notes 1. Except where the context otherwise requires, the headings of this chapter apply only to: (a) Separate chemically defined organic compounds, whether or not containing impurities; (b) Mixtures of two or more isomers of the same organic compound (whether or not containing impurities), except mixtures of acyclic hydrocarbon isomers (other than stereoisomers), whether or not saturated (chapter 27); (c) The products of headings 2936 to 2939 or the sugar ethers and sugar esters, and their salts, of heading 2940, or the products of heading 2941, whether or not chemically defined; (d) Products mentioned in (a), (b) or (c) above dissolved in water; (e) Products mentioned in (a), (b) or (c) above dissolved in other solvents provided that the solution constitutes a normal and necessary method of putting up these products adopted solely for reasons of safety or for transport and that the solvent does not render the product particularly suitable for specific use rather than for general use; (f) The products mentioned in (a), (b), (c), (d) or (e) above with an added stabilizer (including an anticaking agent) necessary for their preservation or transport; (g) The products mentioned in (a), (b), (c), (d), (e) or (f) above with an added antidusting agent or a coloring or odoriferous substance added to facilitate their identification or for safety reasons, provided that the additions do not render the product particularly suitable for specific use rather than for general use; (h) The following products, diluted to standard strengths, for the production of azo dyes: diazonium salts, couplers used for these salts and diazotizable amines and their salts.
    [Show full text]
  • Ricini Oleum
    PHARMACOGNOSY II PHAR306 6th Semester 5th Lecture Prof. Dr. Müberra Koşar Ass. Prof. Dr. Aybike Yektaoğlu Eastern Mediterranean University Faculty of Pharmacy Department of Pharmacognosy PHARMACEUTICAL FIXED OILS AND ANIMAL FATS FIXED OILS & ANIMAL FATS Amygdalae oleum • “Almond oil” • obtained by crushing of the seeds of two varieties Prunus dulcis var. dulcis or P. dulcis var. amara (Rosaceae) in the cold • Almond oil is obtained in the Mediterranean countries (Italy, France, Spain and North Africa) where its culture is obtained • The only difference between the two varieties is the cyanogenic glycoside content of the var. amara FIXED OILS&ANIMAL FATS Amygdalae oleum • seeds carries 40-55% fixed oil • the refined oil mainly contains oleic acid (62-86%), linoleic (20- 30%), palmitic (4-9%) • Amydalae oleum raffinatum (Almond oil, refined) (Eur.Pu.) • Amydalae oleum virginale (Almond oil, virgin) (Eur.Ph.) • major used in cosmetology and dermatology • used as a carrier in oily injectable preparations FIXED OILS&ANIMAL FATS Arachidis oleum • “Arachis oil, Peanut oil” – “Peanut butter” • Arachis hypogaea (Fabaceae) • cultivated in South America, China, India, Australia, and West Africa • due to various genotypes they vary in fatty acid content • the seeds are cold-pressed • they have similar properties as olive oil • most suitable oil for added for embedding purposes into other oils (e.g. olive oil) FIXED OILS&ANIMAL FATS Arachidis oleum - content • seeds carries 40-50% fixed oil • 50-65% oleic acid • 18-30% linoleic acid • 8-10% palmitic
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 De Juan Et Al
    US 200601 10428A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 de Juan et al. (43) Pub. Date: May 25, 2006 (54) METHODS AND DEVICES FOR THE Publication Classification TREATMENT OF OCULAR CONDITIONS (51) Int. Cl. (76) Inventors: Eugene de Juan, LaCanada, CA (US); A6F 2/00 (2006.01) Signe E. Varner, Los Angeles, CA (52) U.S. Cl. .............................................................. 424/427 (US); Laurie R. Lawin, New Brighton, MN (US) (57) ABSTRACT Correspondence Address: Featured is a method for instilling one or more bioactive SCOTT PRIBNOW agents into ocular tissue within an eye of a patient for the Kagan Binder, PLLC treatment of an ocular condition, the method comprising Suite 200 concurrently using at least two of the following bioactive 221 Main Street North agent delivery methods (A)-(C): Stillwater, MN 55082 (US) (A) implanting a Sustained release delivery device com (21) Appl. No.: 11/175,850 prising one or more bioactive agents in a posterior region of the eye so that it delivers the one or more (22) Filed: Jul. 5, 2005 bioactive agents into the vitreous humor of the eye; (B) instilling (e.g., injecting or implanting) one or more Related U.S. Application Data bioactive agents Subretinally; and (60) Provisional application No. 60/585,236, filed on Jul. (C) instilling (e.g., injecting or delivering by ocular ion 2, 2004. Provisional application No. 60/669,701, filed tophoresis) one or more bioactive agents into the Vit on Apr. 8, 2005. reous humor of the eye. Patent Application Publication May 25, 2006 Sheet 1 of 22 US 2006/0110428A1 R 2 2 C.6 Fig.
    [Show full text]
  • ECO-Ssls for Pahs
    Ecological Soil Screening Levels for Polycyclic Aromatic Hydrocarbons (PAHs) Interim Final OSWER Directive 9285.7-78 U.S. Environmental Protection Agency Office of Solid Waste and Emergency Response 1200 Pennsylvania Avenue, N.W. Washington, DC 20460 June 2007 This page intentionally left blank TABLE OF CONTENTS 1.0 INTRODUCTION .......................................................1 2.0 SUMMARY OF ECO-SSLs FOR PAHs......................................1 3.0 ECO-SSL FOR TERRESTRIAL PLANTS....................................4 5.0 ECO-SSL FOR AVIAN WILDLIFE.........................................8 6.0 ECO-SSL FOR MAMMALIAN WILDLIFE..................................8 6.1 Mammalian TRV ...................................................8 6.2 Estimation of Dose and Calculation of the Eco-SSL ........................9 7.0 REFERENCES .........................................................16 7.1 General PAH References ............................................16 7.2 References Used for Derivation of Plant and Soil Invertebrate Eco-SSLs ......17 7.3 References Rejected for Use in Derivation of Plant and Soil Invertebrate Eco-SSLs ...............................................................18 7.4 References Used in Derivation of Wildlife TRVs .........................25 7.5 References Rejected for Use in Derivation of Wildlife TRV ................28 i LIST OF TABLES Table 2.1 PAH Eco-SSLs (mg/kg dry weight in soil) ..............................4 Table 3.1 Plant Toxicity Data - PAHs ..........................................5 Table 4.1
    [Show full text]
  • OECD Environment Health and Safety Publications Series on Testing and Assessment No
    OECD Environment Health and Safety Publications Series on Testing and Assessment No. 21 Detailed Review Paper Appraisal of Test Methods for Sex Hormone Disrupting Chemicals Environment Directorate ORGANISATION FOR ECONOMIC CO-OPERATION AND DEVELOPMENT Paris May 2001 1 Also Published in the Series Testing and Assessment: No. 1, Guidance Document for the Development of OECD Guidelines for Testing of Chemicals (1993; reformatted 1995) No. 2, Detailed Review Paper on Biodegradability Testing (1995) No. 3, Guidance Document for Aquatic Effects Assessment (1995) No. 4, Report of the OECD Workshop on Environmental Hazard/Risk Assessment (1995) No. 5, Report of the SETAC/OECD Workshop on Avian Toxicity Testing (1996) No. 6, Report of the Final Ring-test of the Daphnia magna Reproduction Test (1997) No. 7, Guidance Document on Direct Phototransformation of Chemicals in Water (1997) No. 8, Report of the OECD Workshop on Sharing Information about New Industrial Chemicals Assessment (1997) No. 9 Guidance Document for the Conduct of Studies of Occupational Exposure to Pesticides During Agricultural Application (1997) No. 10, Report of the OECD Workshop on Statistical Analysis of Aquatic Toxicity Data (1998) No. 11, Detailed Review Paper on Aquatic Testing Methods for Pesticides and industrial Chemicals (1998) No. 12, Detailed Review Document on Classification Systems for Germ Cell Mutagenicity in OECD Member Countries (1998) No. 13, Detailed Review Document on Classification Systems for Sensitising Substances in OECD Member Countries 1998) No. 14, Detailed Review Document on Classification Systems for Eye Irritation/Corrosion in OECD Member Countries (1998) No. 15, Detailed Review Document on Classification Systems for Reproductive Toxicity in OECD Member Countries (1998) No.
    [Show full text]
  • The Natural Compounds Atraric Acid and N-Butylbenzene-Sulfonamide
    The natural compounds atraric acid and N-butylbenzene-sulfonamide as antagonists of the human androgen receptor and inhibitors of prostate cancer cell growth Daniela Roell, Aria Baniahmad To cite this version: Daniela Roell, Aria Baniahmad. The natural compounds atraric acid and N-butylbenzene-sulfonamide as antagonists of the human androgen receptor and inhibitors of prostate cancer cell growth. Molec- ular and Cellular Endocrinology, Elsevier, 2010, 332 (1-2), pp.1. 10.1016/j.mce.2010.09.013. hal- 00654968 HAL Id: hal-00654968 https://hal.archives-ouvertes.fr/hal-00654968 Submitted on 24 Dec 2011 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. Accepted Manuscript Title: The natural compounds atraric acid and N-butylbenzene-sulfonamide as antagonists of the human androgen receptor and inhibitors of prostate cancer cell growth Authors: Daniela Roell, Aria Baniahmad PII: S0303-7207(10)00474-0 DOI: doi:10.1016/j.mce.2010.09.013 Reference: MCE 7644 To appear in: Molecular and Cellular Endocrinology Received date: 29-6-2010 Revised date: 3-9-2010 Accepted date: 27-9-2010 Please cite this article as: Roell, D., Baniahmad, A., The natural compounds atraric acid and N-butylbenzene-sulfonamide as antagonists of the human androgen receptor and inhibitors of prostate cancer cell growth, Molecular and Cellular Endocrinology (2010), doi:10.1016/j.mce.2010.09.013 This is a PDF file of an unedited manuscript that has been accepted for publication.
    [Show full text]
  • Effect of Surfactant–Bile Interactions on the Solubility of Hydrophobic
    Article Cite This: Mol. Pharmaceutics 2018, 15, 5741−5753 pubs.acs.org/molecularpharmaceutics Effect of Surfactant−Bile Interactions on the Solubility of Hydrophobic Drugs in Biorelevant Dissolution Media Zahari Vinarov,*,† Vladimir Katev,† Nikola Burdzhiev,‡ Slavka Tcholakova,† and Nikolai Denkov† † Department of Chemical and Pharmaceutical Engineering, Faculty of Chemistry and Pharmacy, Sofia University, 1164 Sofia, Bulgaria ‡ Department of Organic Chemistry and Pharmacognosy, Faculty of Chemistry and Pharmacy, Sofia University, 1164 Sofia, Bulgaria *S Supporting Information ABSTRACT: Biorelevant dissolution media (BDM) methods are commonly employed to investigate the oral absorption of poorly water-soluble drugs. Despite the significant progress in this area, the effect of commonly employed pharmaceutical excipients, such as surfactants, on the solubility of drugs in BDM has not been characterized in detail. The aim of this study is to clarify the impact of surfactant−bile interactions on drug solubility by using a set of 12 surfactants, 3 model hydrophobic drugs (fenofibrate, danazol, and progesterone) and two types of BDM (porcine bile extract and sodium taurodeoxycholate). Drug precipitation and sharp nonlinear decrease in the solubility of all studied drugs is observed when drug-loaded ionic surfactant micelles are introduced in solutions of both BDM, whereas the drugs remain solubilized in the mixtures of nonionic polysorbate surfactants + BDM. One-dimensional and diffusion-ordered 1H NMR spectroscopy show that mixed bile salt + surfactant micelles with low drug solubilization capacity are formed for the ionic surfactants. On the other hand, separate surfactant-rich and bile salt-rich micelles coexist in the nonionic polysorbate surfactant + bile salt mixtures, explaining the better drug solubility in these systems.
    [Show full text]
  • Pp375-430-Annex 1.Qxd
    ANNEX 1 CHEMICAL AND PHYSICAL DATA ON COMPOUNDS USED IN COMBINED ESTROGEN–PROGESTOGEN CONTRACEPTIVES AND HORMONAL MENOPAUSAL THERAPY Annex 1 describes the chemical and physical data, technical products, trends in produc- tion by region and uses of estrogens and progestogens in combined estrogen–progestogen contraceptives and hormonal menopausal therapy. Estrogens and progestogens are listed separately in alphabetical order. Trade names for these compounds alone and in combination are given in Annexes 2–4. Sales are listed according to the regions designated by WHO. These are: Africa: Algeria, Angola, Benin, Botswana, Burkina Faso, Burundi, Cameroon, Cape Verde, Central African Republic, Chad, Comoros, Congo, Côte d'Ivoire, Democratic Republic of the Congo, Equatorial Guinea, Eritrea, Ethiopia, Gabon, Gambia, Ghana, Guinea, Guinea-Bissau, Kenya, Lesotho, Liberia, Madagascar, Malawi, Mali, Mauritania, Mauritius, Mozambique, Namibia, Niger, Nigeria, Rwanda, Sao Tome and Principe, Senegal, Seychelles, Sierra Leone, South Africa, Swaziland, Togo, Uganda, United Republic of Tanzania, Zambia and Zimbabwe America (North): Canada, Central America (Antigua and Barbuda, Bahamas, Barbados, Belize, Costa Rica, Cuba, Dominica, El Salvador, Grenada, Guatemala, Haiti, Honduras, Jamaica, Mexico, Nicaragua, Panama, Puerto Rico, Saint Kitts and Nevis, Saint Lucia, Saint Vincent and the Grenadines, Suriname, Trinidad and Tobago), United States of America America (South): Argentina, Bolivia, Brazil, Chile, Colombia, Dominican Republic, Ecuador, Guyana, Paraguay,
    [Show full text]
  • Exposure to Female Hormone Drugs During Pregnancy
    British Journal of Cancer (1999) 80(7), 1092–1097 © 1999 Cancer Research Campaign Article no. bjoc.1998.0469 Exposure to female hormone drugs during pregnancy: effect on malformations and cancer E Hemminki, M Gissler and H Toukomaa National Research and Development Centre for Welfare and Health, Health Services Research Unit, PO Box 220, 00531 Helsinki, Finland Summary This study aimed to investigate whether the use of female sex hormone drugs during pregnancy is a risk factor for subsequent breast and other oestrogen-dependent cancers among mothers and their children and for genital malformations in the children. A retrospective cohort of 2052 hormone-drug exposed mothers, 2038 control mothers and their 4130 infants was collected from maternity centres in Helsinki from 1954 to 1963. Cancer cases were searched for in national registers through record linkage. Exposures were examined by the type of the drug (oestrogen, progestin only) and by timing (early in pregnancy, only late in pregnancy). There were no statistically significant differences between the groups with regard to mothers’ cancer, either in total or in specified hormone-dependent cancers. The total number of malformations recorded, as well as malformations of the genitals in male infants, were higher among exposed children. The number of cancers among the offspring was small and none of the differences between groups were statistically significant. The study supports the hypothesis that oestrogen or progestin drug therapy during pregnancy causes malformations among children who were exposed in utero but does not support the hypothesis that it causes cancer later in life in the mother; the power to study cancers in offspring, however, was very low.
    [Show full text]
  • Classification Decisions Taken by the Harmonized System Committee from the 47Th to 60Th Sessions (2011
    CLASSIFICATION DECISIONS TAKEN BY THE HARMONIZED SYSTEM COMMITTEE FROM THE 47TH TO 60TH SESSIONS (2011 - 2018) WORLD CUSTOMS ORGANIZATION Rue du Marché 30 B-1210 Brussels Belgium November 2011 Copyright © 2011 World Customs Organization. All rights reserved. Requests and inquiries concerning translation, reproduction and adaptation rights should be addressed to [email protected]. D/2011/0448/25 The following list contains the classification decisions (other than those subject to a reservation) taken by the Harmonized System Committee ( 47th Session – March 2011) on specific products, together with their related Harmonized System code numbers and, in certain cases, the classification rationale. Advice Parties seeking to import or export merchandise covered by a decision are advised to verify the implementation of the decision by the importing or exporting country, as the case may be. HS codes Classification No Product description Classification considered rationale 1. Preparation, in the form of a powder, consisting of 92 % sugar, 6 % 2106.90 GRIs 1 and 6 black currant powder, anticaking agent, citric acid and black currant flavouring, put up for retail sale in 32-gram sachets, intended to be consumed as a beverage after mixing with hot water. 2. Vanutide cridificar (INN List 100). 3002.20 3. Certain INN products. Chapters 28, 29 (See “INN List 101” at the end of this publication.) and 30 4. Certain INN products. Chapters 13, 29 (See “INN List 102” at the end of this publication.) and 30 5. Certain INN products. Chapters 28, 29, (See “INN List 103” at the end of this publication.) 30, 35 and 39 6. Re-classification of INN products.
    [Show full text]
  • Annex 2 Composition of Oral and Injectable Estrogen–Progestogen Contraceptives
    ANNEX 2 COMPOSITION OF ORAL AND INJECTABLE ESTROGEN–PROGESTOGEN CONTRACEPTIVES Annex 2 lists the composition of brands of estrogen–progestogen preparations used in combined injectables (Table 1), combined oral (Table 2) and phasic oral (Table 3) contraceptives. The countries in which these formulations are used are noted. Are listed only those brands for which availability was reported. The source of these tables is the International Planned Parenthood Foundation (IPPF). Data have been taken from the IPPF 2002 website [http://contraceptive.ippf.org] at the time of the monograph meeting (June 2005). This online site is regularly updated. Table 1. Combined injectables Brand name Composition Countries of availability Acefil Dihydroxyprogesterone acetophenide 150 mg Paraguay + estradiol enanthate 10 mg Agurin Dihydroxyprogesterone acetophenide 150 mg Chile + estradiol enanthate 10 mg Anafertin Dihydroxyprogesterone acetophenide 75 mg El Salvador, Mexico + estradiol enanthate 5 mg Ciclofem Medroxyprogesterone acetate 25 mg Guatemala + estradiol cypionate 5 mg Ciclofemina Medroxyprogesterone acetate 25 mg El Salvador + estradiol cypionate 5 mg Ciclomes Dihydroxyprogesterone acetophenide 150 mg Paraguay + estradiol enanthate 10 mg Ciclovular Dihydroxyprogesterone acetophenide 150 mg Brazil + estradiol enanthate 10 mg Clinomin Dihydroxyprogesterone acetophenide 150 mg Paraguay + estradiol enanthate 10 mg Cyclofem Medroxyprogesterone acetate 25 mg Chile, Indonesia, Malaysia, Mexico, + estradiol cypionate 5 mg Panama, Zimbabwe Cyclofemina Medroxyprogesterone
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2008/0299054 A1 Chandar Et Al
    US 20080299054A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2008/0299054 A1 Chandar et al. (43) Pub. Date: Dec. 4, 2008 (54) PERSONAL CARE COMPOSITIONS WITH Publication Classification ENHANCED FRAGRANCE DELVERY (51) Int. Cl. (75) Inventors: Prem Chandar, Closter, NJ (US); A6IR 8/34 (2006.01) Lin Yang, Woodbridge, CT (US) A6II 3/14 (2006.01) A6II 3/17 (2006.01) Correspondence Address: UNILEVER PATENT GROUP (52) U.S. Cl. .............. 424/54; 424/59: 424/65; 424/70.1; 800 SYLVANAVENUE, AG West S. Wing 514/588 ENGLEWOOD CLIFFS, NJ 07632-3100 (US) (57) ABSTRACT (73) Assignee: CONOPCO, INC., d/b/a UNILEVER, Englewood Cliffs, NJ A personal care product is provided which includes a fra (US) grance, a Substituted urea and a quaternary ammonium salt. The Substituted urea and quaternary ammonium salt operate (21) Appl. No.: 11/755,009 together as a scent boosting system to enhance Volatilization offragrance components upon the personal care composition (22) Filed: May 30, 2007 being first applied to human skin or hair. US 2008/0299054 A1 Dec. 4, 2008 PERSONAL CARE COMPOSITIONS WITH structure AB, wherein A is a cationic charged compo ENHANCED FRAGRANCE DELVERY nent of the salt AB, B is an anionic charged component of the salt AB, and BACKGROUND OF THE INVENTION 0013 A has a single quaternized nitrogen atom, at least two hydroxy groups and a molecular weight no 0001 1. Field of the Invention higher than about 250. 0002 The invention concerns personal care compositions which upon application to a human body Surface quickly release fragrance components thereby improving aesthetics DETAILED DESCRIPTION OF THE INVENTION of these compositions.
    [Show full text]